In a nutshell The study compared patient-reported outcomes (PRO) in patients receiving continuous androgen deprivation therapy (CADT) vs intermittent androgen deprivation therapy (IADT) for locally advanced prostate cancer (PCa). The study reported that PROs were significantly improved with IADT. Some background ADT is a hormonal therapy...
Read More
In a nutshell This study explored the outcomes of statin (cholesterol-lowering drugs) treatment in patients with prostate cancer (PCa) undergoing androgen deprivation therapy (ADT). The authors found that the combination of statins and ADT improved the outcomes of these patients and intermittent ADT (IADT) increased the time...
Read More
In a nutshell This study aims to evaluate if giving radiotherapy to both the areas the tumor has spread (metastases), along with the prostate tumor, will improve the survival of patients with prostate cancer (PC) and few metastases (oligometastatic disease). This study suggested that this treatment could benefit patients with PC and few...
Read More
In a nutshell The study compared the quality of life (QoL) of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (Jevtana) compared to abiraterone (Zytiga) or enzalutamide (Xtandi). The authors found that cabazitaxel did not reduce QoL in such patients. Some background Patients with mCRPC...
Read More
In a nutshell This study was carried out to assess different dosing regimens of hypofractionated stereotactic body radiotherapy (SBRT) in patients with prostate cancer. The study found that both doses were associated with high effectiveness and manageable side effects. Some background Radiotherapy is an effective treatment for early-stage PC....
Read More
In a nutshell This trial is examining the effectiveness of cabozantinib (Cabometyx) combined with atezolizumab (Tecentriq) for metastatic castration-resistant prostate cancer (mCRPC; cancer that is no longer responding to hormone therapy). The main outcomes to be measured are progression-free survival (PFS) and overall survival (OS) of...
Read More
In a nutshell This article investigated the safety and effectiveness of Lutetium-177 PSMA (LuPSMA) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The authors concluded that LuPSMA is a safe and effective treatment option for these patients. Some background mCRPC is cancer which has spread from its original site...
Read MoreIn a nutshell This phase 2 trial will investigate the safety and effectiveness of nivolumab (Opdivo) in recurrent prostate cancer (PC). The main outcome will be disease control. This trial is recruiting at two locations in Boston, MA, US. The details Prostate cancer (PC) is a highly treatable cancer in men. Patients are usually...
Read More
In a nutshell The authors aimed to determine patient outcomes following partial gland ablation compared to robot-assisted radical prostate surgery in men with low- and intermediate- risk prostate cancer. The authors concluded that men with cancer confined to the prostate benefited from partial gland ablation, as it was more successful with fewer side...
Read MoreIn a nutshell The aim of this trial was to determine the difference in quality of life on urination when treated with low dose rate (LDR) and high dose rate (HDR) brachytherapy. This study is being conducted in Kelowna, British Columbia, Canada. The details Brachytherapy is a form of radiation therapy that places radioactive material either within...
Read MoreIn a nutshell The authors aimed to determine how anxiety and uncertainty affects men with prostate cancer who are undergoing active surveillance. The authors concluded that uncertainty and urinary complications promote anxiety in men on active surveillance for prostate cancer. They also recommend patient education and management of urinary...
Read More
In a nutshell The aim of this study was to see if ultrasounds could be used as a tool to monitor low-risk prostate cancer patients in active surveillance. It was concluded that ultrasounds can be used to monitor changes in prostate cancer, and could extend the time between biopsies. Some background Low-risk prostate cancer is cancer that has not...
Read More
